Progranulin: A promising biomarker and therapeutic target for fibrotic diseases
Acta Pharmaceutica Sinica B · 2024-08 · 14 (8) · 3312-3326
DOI: 10.1016/j.apsb.2024.04.026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2024-08. Verfasst von Fan Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200000, C…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NSFC.
Abstract (Originalsprache)
Progranulin (PGRN), a multifunctional growth factor-like protein expressed by a variety of cell types, serves an important function in the physiologic and pathologic processes of fibrotic diseases, including wound healing and the inflammatory response. PGRN was discovered to inhibit pro-inflammation effect by competing with tumor necrosis factor-alpha (TNF-α) binding to TNF receptors. Notably, excessive tissue repair in the development of inflammation causes tissue fibrosis. Previous investigations have indicated the significance of PGRN in regulating inflammatory responses. Recently, multiple studies have shown that PGRN was linked to fibrogenesis, and was considered to monitor the formation of fibrosis in multiple organs, including liver, cardiovascular, lung and skin. This paper is a comprehensive review summarizing our current knowledge of PGRN, from its discovery to the role in fibrosis. This is followed by an in-depth look at the characteristics of PGRN, consisting of its structure, basic function and intracellular signaling. Finally, we will discuss the potential of PGRN in the diagnosis and treatment of fibrosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200000, China.
- Department of Ophthalmology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei 230022, China.
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei 230022, China.
Förderung
- NSFC
Zitieren
APA
Yang, F., Cheng, M. H., Pan, H. F., & Gao, J. (2024). Progranulin: A promising biomarker and therapeutic target for fibrotic diseases. Acta Pharmaceutica Sinica B, 14(8), 3312-3326. https://doi.org/10.1016/j.apsb.2024.04.026
Vancouver
Yang F, Cheng MH, Pan HF, Gao J. Progranulin: A promising biomarker and therapeutic target for fibrotic diseases. Acta Pharmaceutica Sinica B. 2024;14(8):3312-3326. doi:10.1016/j.apsb.2024.04.026
BibTeX
@article{Yang2024,
author = {Yang, Fan and Cheng, Ming-Han and Pan, Hai-Feng and Gao, Jian},
title = {Progranulin: A promising biomarker and therapeutic target for fibrotic diseases},
journal = {Acta Pharmaceutica Sinica B},
year = {2024},
volume = {14},
number = {8},
pages = {3312--3326},
doi = {10.1016/j.apsb.2024.04.026}
}
EUVIMED